Nasdaq · Healthcare
Equillium, Inc. (EQ)
As-reported financials and recent SEC filings for Equillium, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
—
Net income
$-22.4M
Net margin
—
Diluted EPS
$-0.39
ROE
-78.3%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $41.1M | $36.1M | $15.8M | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-23.6M | $-8.3M | $-14.5M | $-62.1M | $-37.8M |
| Net income | $-22.4M | $-8.1M | $-13.3M | $-62.4M | $-39.1M |
| Diluted EPS | $-0.39 | $-0.23 | $-0.38 | $-1.85 | $-1.36 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →1442026-06-04
View on EDGAR →42026-05-29
View on EDGAR →42026-05-29
View on EDGAR →42026-05-29
View on EDGAR →42026-05-29
View on EDGAR →Largest Healthcare peers
Go deeper on EQ
Search Equillium, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.